George L. Bakris

113.9k total citations · 46 hit papers
849 papers, 68.8k citations indexed

About

George L. Bakris is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Nephrology. According to data from OpenAlex, George L. Bakris has authored 849 papers receiving a total of 68.8k indexed citations (citations by other indexed papers that have themselves been cited), including 547 papers in Cardiology and Cardiovascular Medicine, 396 papers in Endocrinology, Diabetes and Metabolism and 204 papers in Nephrology. Recurrent topics in George L. Bakris's work include Blood Pressure and Hypertension Studies (450 papers), Hormonal Regulation and Hypertension (220 papers) and Diabetes Treatment and Management (168 papers). George L. Bakris is often cited by papers focused on Blood Pressure and Hypertension Studies (450 papers), Hormonal Regulation and Hypertension (220 papers) and Diabetes Treatment and Management (168 papers). George L. Bakris collaborates with scholars based in United States, United Kingdom and Germany. George L. Bakris's co-authors include William C. Cushman, Henry R. Black, Jackson T. Wright, Aram V. Chobanian, Joseph L. Izzo, Barry J. Materson, Suzanne Oparil, Daniel W. Jones, Edward J. Roccella and Lee A. Green and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

George L. Bakris

825 papers receiving 66.1k citations

Hit Papers

Seventh Report of the Joint National Committee on Prevent... 2000 2026 2008 2017 2003 2013 2010 2014 2008 2.5k 5.0k 7.5k 10.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    2003 10.3k citations Aram V. Chobanian, George L. Bakris et al. Hypertension profile →
  2. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
    2013 1.9k citations Christopher P. Cannon, George L. Bakris et al. New England Journal of Medicine profile →
  3. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
    2010 1.6k citations Loren F. Hiratzka, George L. Bakris et al. Circulation profile →
  4. A Controlled Trial of Renal Denervation for Resistant Hypertension
    2014 1.4k citations Deepak L. Bhatt, David E. Kandzari et al. New England Journal of Medicine profile →
  5. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
    2008 1.3k citations Michael A. Weber, George L. Bakris et al. New England Journal of Medicine profile →
  6. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
    2010 1.2k citations Loren F. Hiratzka, George L. Bakris et al. Journal of the American College of Cardiology profile →
  7. THE SEVENTH REPORT OF THE JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE. THE JNC 7 REPORT
    2003 1.2k citations Aram V. Chobanian, George L. Bakris et al. profile →
  8. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease
    2006 1.1k citations Adeera Levin, George L. Bakris et al. profile →
  9. Preserving renal function in adults with hypertension and diabetes: A consensus approach
    2000 1.1k citations George L. Bakris, Katherine R. Tuttle et al. profile →
  10. A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease
    2003 859 citations Carl J. Pepine, Franz H. Messerli et al. profile →
  11. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
    2006 788 citations George L. Bakris, Vivian Fonseca et al. Diabetes Care profile →
  12. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
    2013 784 citations Dick de Zeeuw, George L. Bakris et al. New England Journal of Medicine profile →
  13. Diabetic Kidney Disease: A Report From an ADA Consensus Conference
    2014 783 citations Katherine R. Tuttle, George L. Bakris et al. Diabetes Care profile →
  14. Hypertension
    2018 738 citations George L. Bakris et al. profile →
  15. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
    2011 710 citations David B. Sacks, Mark A. Arnold et al. profile →
  16. Diabetic Kidney Disease: A Report From an ADA Consensus Conference
    2014 669 citations Katherine R. Tuttle, George L. Bakris et al. profile →
  17. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
    2024 656 citations Vlado Perkovic, Katherine R. Tuttle et al. New England Journal of Medicine profile →
  18. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
    2018 655 citations George L. Bakris, John M. Flack et al. Hypertension profile →
  19. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: Executive Summary
    2010 642 citations Loren F. Hiratzka, George L. Bakris et al. Circulation profile →
  20. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
    2021 578 citations Gerasimos Filippatos, Bertram Pitt et al. profile →
  21. Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine
    2000 565 citations George L. Bakris, Matthew R. Weir profile →
  22. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
    2015 551 citations Christopher P. Cannon, William C. Cushman et al. profile →
  23. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension
    2004 536 citations George L. Bakris, Vivian Fonseca et al. profile →
  24. The pathogenesis of diabetic nephropathy
    2008 519 citations George L. Bakris et al. profile →
  25. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
    2016 505 citations George L. Bakris, Yehuda Handelsman et al. profile →
  26. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
    2015 493 citations George L. Bakris, Rajiv Agarwal et al. profile →
  27. Diabetes and Hypertension: A Position Statement by the American Diabetes Association
    2017 459 citations Ian H. de Boer, Erin D. Michos et al. Diabetes Care profile →
  28. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
    2014 453 citations Matthew R. Weir, George L. Bakris et al. New England Journal of Medicine profile →
  29. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation
    2018 451 citations George L. Bakris et al. profile →
  30. Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease
    2010 445 citations George L. Bakris, Carl J. Pepine et al. profile →
  31. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
    2013 418 citations George L. Bakris et al. profile →
  32. Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension
    2011 411 citations John D. Bisognano, George L. Bakris et al. Journal of the American College of Cardiology profile →
  33. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
    2011 406 citations Carl J. Pepine, George L. Bakris et al. Circulation profile →
  34. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
    2022 386 citations Ian H. de Boer, Katherine R. Tuttle et al. Diabetes Care profile →
  35. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
    2020 351 citations George L. Bakris et al. profile →
  36. Molecular mechanisms and therapeutic targets for diabetic kidney disease
    2022 349 citations Katherine R. Tuttle, Rajiv Agarwal et al. profile →
  37. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease
    2015 312 citations George L. Bakris, Bertram Pitt et al. profile →
  38. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
    2022 167 citations Ian H. de Boer, Katherine R. Tuttle et al. profile →
  39. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
    2021 161 citations George L. Bakris, Thomas Idorn et al. Circulation profile →
  40. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
    2023 149 citations George L. Bakris et al. New England Journal of Medicine profile →
  41. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
    2023 147 citations Peter Rossing, Florian M.M. Baeres et al. profile →
  42. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
    2023 133 citations Sandra Naaman, George L. Bakris Diabetes Care profile →
  43. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
    2023 132 citations Hiddo J.L. Heerspink, Clare Arnott et al. Circulation profile →
  44. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
    2023 116 citations David B. Sacks, Mark A. Arnold et al. Diabetes Care profile →
  45. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
    2024 74 citations Johannes F.E. Mann, Peter Rossing et al. profile →
  46. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
    2024 50 citations Richard E. Pratley, Katherine R. Tuttle et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
George L. Bakris United States 116 35.6k 25.6k 12.1k 10.8k 10.8k 849 68.8k
Dick de Zeeuw Netherlands 95 19.0k 0.5× 19.5k 0.8× 20.0k 1.6× 7.7k 0.7× 6.3k 0.6× 825 53.1k
Marc A. Pfeffer United States 139 63.0k 1.8× 17.6k 0.7× 6.0k 0.5× 26.3k 2.4× 8.9k 0.8× 596 95.5k
John J.V. McMurray United Kingdom 161 87.0k 2.4× 30.4k 1.2× 8.4k 0.7× 22.7k 2.1× 16.5k 1.5× 1.5k 131.6k
Martin G. Larson United States 142 53.4k 1.5× 9.6k 0.4× 4.4k 0.4× 12.7k 1.2× 8.0k 0.7× 587 89.4k
Ramachandran S. Vasan United States 146 57.4k 1.6× 16.0k 0.6× 4.7k 0.4× 13.8k 1.3× 8.8k 0.8× 955 108.8k
Tom Greene United States 100 17.9k 0.5× 11.4k 0.4× 39.1k 3.2× 12.6k 1.2× 12.4k 1.1× 481 81.4k
Giuseppe Mancia Italy 109 46.3k 1.3× 11.8k 0.5× 4.0k 0.3× 10.8k 1.0× 4.2k 0.4× 1.3k 63.5k
Josef Coresh United States 133 30.8k 0.9× 16.9k 0.7× 50.9k 4.2× 16.1k 1.5× 16.2k 1.5× 952 116.0k
Aaron R. Folsom United States 139 26.9k 0.8× 10.3k 0.4× 3.2k 0.3× 11.1k 1.0× 8.4k 0.8× 867 75.6k
Jiang He United States 101 19.7k 0.6× 10.7k 0.4× 5.9k 0.5× 5.8k 0.5× 3.4k 0.3× 668 55.4k

Countries citing papers authored by George L. Bakris

Since Specialization
Citations

This map shows the geographic impact of George L. Bakris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George L. Bakris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George L. Bakris more than expected).

Fields of papers citing papers by George L. Bakris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George L. Bakris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George L. Bakris. The network helps show where George L. Bakris may publish in the future.

Co-authorship network of co-authors of George L. Bakris

This figure shows the co-authorship network connecting the top 25 collaborators of George L. Bakris. A scholar is included among the top collaborators of George L. Bakris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George L. Bakris. George L. Bakris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pratley, Richard E., Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology. 84(17). 1615–1628. 50 indexed citations breakdown →
2.
Perkovic, Vlado, Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 391(2). 109–121. 656 indexed citations breakdown →
3.
Bakris, George L., et al.. (2024). A review of novel endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An update. European Journal of Pharmacology. 979. 176752–176752. 2 indexed citations
4.
Mahfoud, Felix, Raymond R. Townsend, Giuseppe Mancia, et al.. (2024). POOLED, LONG-TERM ANALYSIS OF THE GLOBAL SYMPLICITY CLINICAL TRIAL PROGRAM OF RADIOFREQUENCY RENAL DENERVATION FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION. Journal of Hypertension. 42(Suppl 1). e17–e17. 2 indexed citations
5.
Biegus, Jan, JoAnn Lindenfeld, G. Michael Felker, et al.. (2024). Design and Rationale of the eLym™ System for Decompensation of Excess Lymphatic Fluid via the Thoracic Duct in Acute Heart Failure (DELTA-HF). ESC Heart Failure. 12(3). 1719–1726. 3 indexed citations
6.
Sacks, David B., Mark A. Arnold, George L. Bakris, et al.. (2023). Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 46(10). e151–e199. 116 indexed citations breakdown →
7.
Handelsman, Yehuda, Javed Butler, George L. Bakris, et al.. (2023). Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and its Complications. 37(2). 108389–108389. 43 indexed citations
8.
Bakris, George L., John M. Flack, Krzysztof Narkiewicz, et al.. (2023). Effects of Aprocitentan for Blood Pressure Lowering and Proteinuria in Patients with CKD and Resistant Hypertension. Journal of the American Society of Nephrology. 34(11S). 56–56. 2 indexed citations
9.
Naaman, Sandra & George L. Bakris. (2023). Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 46(9). 1574–1586. 133 indexed citations breakdown →
10.
Charytan, David M., Kenneth W. Mahaffey, Meg Jardine, et al.. (2023). Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Research & Care. 11(3). e003270–e003270. 3 indexed citations
11.
Agarwal, Rajiv, Stefan D. Anker, Bertram Pitt, et al.. (2021). Association of Urine Albumin-to-Creatinine Ratio and Its Early Change with Cardiorenal Outcomes in FIDELIO-DKD: A Mediation Analysis. Journal of the American Society of Nephrology. 32(10S). B5–B5.
12.
Hanrahan, John P., Ian H. de Boer, George L. Bakris, et al.. (2020). Effect of Praliciguat, a Once-Daily, Oral Soluble Guanylate Cyclase Stimulator, on Albuminuria in Patients with Diabetic Kidney Disease: A Randomized, Double-Blind, Phase 2 Trial. Journal of the American Society of Nephrology. 31(10S). 351–351. 1 indexed citations
13.
Leeuw, Peter W. de, John D. Bisognano, George L. Bakris, et al.. (2017). Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy. Hypertension. 69(5). 836–843. 83 indexed citations
14.
Hiratzka, Loren F., George L. Bakris, Joshua A. Beckman, et al.. (2010). 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. Circulation. 121(13). e266–369. 1621 indexed citations breakdown →
15.
Bakris, George L. & Eberhard Ritz. (2009). The message for World Kidney Day 2009: hypertension and kidney disease—a marriage that should be prevented. Clinical and Experimental Nephrology. 13(1). 96–99.
16.
Mancia, Giuseppe, Franz H. Messerli, George L. Bakris, et al.. (2007). Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 50(2). 299–305. 134 indexed citations
17.
Zillich, Alan J., Jay Garg, Sanjib Basu, George L. Bakris, & Barry L. Carter. (2006). Thiazide Diuretics, Potassium, and the Development of Diabetes. Hypertension. 48(2). 219–224. 289 indexed citations
18.
19.
Chobanian, Aram V., George L. Bakris, Henry R. Black, et al.. (2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 42(6). 1206–1252. 10256 indexed citations breakdown →
20.
Garg, Jay & George L. Bakris. (2002). Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports. 4(3). 185–190. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dick de Zeeuw Breakdown of academic impact, for papers by Marc A. Pfeffer Breakdown of academic impact, for papers by John J.V. McMurray Breakdown of academic impact, for papers by Martin G. Larson Breakdown of academic impact, for papers by Ramachandran S. Vasan Breakdown of academic impact, for papers by Tom Greene Breakdown of academic impact, for papers by Giuseppe Mancia Breakdown of academic impact, for papers by Josef Coresh Breakdown of academic impact, for papers by Aaron R. Folsom Breakdown of academic impact, for papers by Jiang He
Rankless by CCL
2026